Plain-English translation of NCT05536505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
After you have surgery to remove your lung cancer, this trial uses special blood tests to look for tiny traces of cancer cells. Depending on what those tests show, you may take icotinib—a targeted medication designed for your type of lung cancer—or simply be monitored closely. The goal is to give medication only to people who really need it, based on what their blood reveals.
Some people with lung cancer have cancer cells remaining after surgery even though the surgery appeared successful. This trial is testing whether using blood tests to detect these hidden cancer traces can help doctors decide who should receive treatment right away and who can safely wait, potentially avoiding unnecessary medication.
You likely qualify if…
You likely don't qualify if…
You will have blood tests at one week and one month after your surgery to check for cancer traces. Based on these results, you may start taking the medication or simply be monitored. If you take the medication, you'll have follow-up blood tests every three months to see if the cancer traces disappear. Once they do, you can stop the medication and continue monitoring—if traces reappear, you restart treatment. The study lasts at least 12 weeks, but typically involves ongoing monitoring for longer.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China